[{"from": "human", "value": "Please give me some details about this molecule. [C][C][Branch1][C][C][Branch2][Branch1][=N][C][C][C][C@@][Branch1][Branch2][C][C][=Branch1][C][=O][O][C][Branch2][Ring2][N][C][=Branch1][C][=O][O][C@H1][C@H1][C][=C][C][=C][Branch2][Ring1][Branch2][C][=C][Ring1][=Branch1][C][C][N][C@@][Ring1][O][Branch1][=Branch1][C][C][C][Ring1][Branch1][C][=C][Ring1][P][O][C][O][C][O][Ring2][Ring1][C][O][O]"}, {"from": "gpt", "value": "The molecule is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate  is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML."}]